Kezar Life Sciences (KZR) News Today $3.98 +0.02 (+0.51%) As of 08/28/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KZR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Kezar Life Sciences to Participate in Two Upcoming Investor ConferencesAugust 28 at 4:01 PM | businesswire.comWilliam Blair Analysts Raise Earnings Estimates for KZRAugust 19, 2025 | americanbankingnews.comWilliam Blair Reaffirms Their Buy Rating on Kezar Life Sciences (KZR)August 15, 2025 | theglobeandmail.comKezar Life Sciences reports Q2 EPS ($1.87), consensus ($2.32)August 13, 2025 | msn.comKezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 13, 2025 | businesswire.comKezar Life Sciences Says FDA Lifts Clinical HoldJuly 16, 2025 | marketwatch.comKezar Life Sciences stock gains after FDA lifts partial clinical holdJuly 16, 2025 | uk.investing.comKezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune HepatitisJuly 15, 2025 | businesswire.comKezar Life Sciences Inc. Research & Ratings | KZR | Barron'sJuly 13, 2025 | barrons.comKZR | Kezar Life Sciences Inc. Stock Overview (U.S.: Nasdaq) - Barron'sJune 30, 2025 | barrons.comKezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | businesswire.comKezar Life Sciences price target lowered to $7 from $9 at Wells FargoMarch 27, 2025 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Roche Holding AG (OtherRHHVF), Kezar Life Sciences (KZR) and Axsome Therapeutics (AXSM)March 26, 2025 | markets.businessinsider.comKezar Life Sciences reports topline results from PORTOLA trialMarch 26, 2025 | markets.businessinsider.comKezar Life Sciences, Inc. (KZR) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call (Transcript)March 25, 2025 | seekingalpha.comKezar drops after Q4 results and mid-stage data for lead assetMarch 25, 2025 | msn.comKezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial ResultsMarch 25, 2025 | businesswire.comKezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025March 24, 2025 | businesswire.comTD Cowen Keeps Their Buy Rating on Kezar Life Sciences (KZR)February 28, 2025 | markets.businessinsider.comPositive Report for Kezar Life Sciences (KZR) from William BlairFebruary 28, 2025 | markets.businessinsider.comWilliam Blair Sticks to Its Hold Rating for Kezar Life Sciences (KZR)February 25, 2025 | markets.businessinsider.comKezar Life Sciences files $400M mixed securities shelfFebruary 6, 2025 | markets.businessinsider.comKezar Life Sciences price target lowered to $9 from $11 at Wells FargoDecember 19, 2024 | markets.businessinsider.comKezar Life Sciences updates shareholder rights agreementDecember 5, 2024 | investing.comHC Wainwright Issues Pessimistic Outlook for KZR EarningsDecember 4, 2024 | marketbeat.comKezar Life Sciences (KZR) Receives a Hold from H.C. WainwrightDecember 2, 2024 | markets.businessinsider.comFY2024 Earnings Estimate for KZR Issued By William BlairNovember 18, 2024 | marketbeat.comKezar struck again with second FDA holdNovember 14, 2024 | msn.comWells Fargo & Company Issues Pessimistic Forecast for Kezar Life Sciences (NASDAQ:KZR) Stock PriceNovember 14, 2024 | marketbeat.comKezar Life Sciences' (KZR) "Market Perform" Rating Reaffirmed at William BlairNovember 13, 2024 | marketbeat.comKezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 13, 2024 | finanznachrichten.deKezar Life Sciences (KZR) Receives a Buy from TD CowenNovember 13, 2024 | markets.businessinsider.comGlancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)November 5, 2024 | businesswire.comKezar Life Sciences Share Price (KZR.US)November 4, 2024 | lse.co.ukKezar Life Sciences (NASDAQ:KZR) Shares Gap Down - Here's What HappenedOctober 30, 2024 | marketbeat.comKezar Life Sciences trading halted, news pendingOctober 30, 2024 | markets.businessinsider.comKezar Life Sciences Stock Scheduled to Reverse Split on Wednesday, October 30th (NASDAQ:KZR)October 28, 2024 | marketbeat.comKezar Life Sciences Announces 1-for-10 Reverse Stock SplitOctober 28, 2024 | finance.yahoo.comKezar Life Sciences Announces One-for-ten Reverse Stock SplitOctober 28, 2024 | markets.businessinsider.comH.C. Wainwright Sticks to Its Hold Rating for Kezar Life Sciences (KZR)October 19, 2024 | markets.businessinsider.comKezar Life Sciences discontinues lupus nephritis programme after fatalitiesOctober 19, 2024 | msn.comKezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights PlanOctober 17, 2024 | stockhouse.comKezar to discontinue mid-stage trial for lupus treatmentOctober 17, 2024 | msn.comKezar Life Rejects Proposal From Concentra; Board Adopts Limited Duration Stockholder Rights PlanOctober 17, 2024 | markets.businessinsider.comKezar stock falls 9% after board rejects Concentra takeover offerOctober 17, 2024 | msn.comPenny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis StudyOctober 17, 2024 | finance.yahoo.comKezar discontinues development of zetomipzomib for lupus nephritisOctober 17, 2024 | msn.comKezar Life Sciences, Inc. (NASDAQ:KZR) Sees Significant Growth in Short InterestOctober 15, 2024 | marketbeat.comKezar Life Sciences (NASDAQ:KZR) Rating Reiterated by HC WainwrightOctober 14, 2024 | marketbeat.comKezar Confirms Receipt of Unsolicited, Non-Binding Acquisition ProposalOctober 10, 2024 | finance.yahoo.com Get Kezar Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KZR Media Mentions By Week KZR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KZR News Sentiment▼0.941.03▲Average Medical News Sentiment KZR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KZR Articles This Week▼21▲KZR Articles Average Week Get the Latest News and Ratings for KZR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Kezar Life Sciences and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies COYA News Today IOBT News Today EQ News Today ADAG News Today BMEA News Today ANEB News Today MGNX News Today SAVA News Today TCRX News Today ANRO News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KZR) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kezar Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kezar Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access